@article{4299db3192d54943a1f411c4808ab895,
title = "Authors' reply to comment What should be the endpoints of a symptomatic drug and its control?",
author = "Ruben Mesa and Claire Harrison",
note = "Funding Information: RM reports research support from Incyte, Gilead, CTI BioPharma, Promedior, Genentech, Lilly, and NS Pharma; and consultancy for Novartis, Galena, and Ariad. CH reports personal fees from CTI BioPharma; research funding from Novartis; speaker funding from CTI BioPharma, Novartis, Sanofi, and Baxter; and advisor fees from CTI BioPharma, Novartis, Gilead, and Baxter.",
year = "2017",
month = nov,
doi = "10.1016/S2352-3026(17)30195-3",
language = "English (US)",
volume = "4",
pages = "e508--e509",
journal = "The Lancet Haematology",
issn = "2352-3026",
publisher = "Lancet Publishing Group",
number = "11",
}